The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 28, 2017

Filed:

Jan. 10, 2012
Applicants:

Arash Ash Alizadeh, San Mateo, CA (US);

Dan Denney, Fremont, CA (US);

Ronald Levy, Stanford, CA (US);

Inventors:

Arash Ash Alizadeh, San Mateo, CA (US);

Dan Denney, Fremont, CA (US);

Ronald Levy, Stanford, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); G01N 33/57426 (2013.01); G01N 33/686 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); G01N 2800/52 (2013.01);
Abstract

Predictive biomarkers identify those patients suffering from immunoglobulin positive (Ig) B lineage malignancies that are responsive to active immunotherapy, where the active immunotherapy comprises vaccination with a tumor-specific idiotype-immunogen. It is shown herein that patient responsiveness to the idiotype-immunogen is dependent upon the sequence of the immunogen, where an immunogen having a low number of tyrosine residues in the CDR1 (herein termed CDR1-Y) regions of one or both of the immunogen heavy and light chains is predictive of a positive anti-tumor response, while a high number of CDR1 tyrosine residues (herein termed CDR1-Y) is predictive of a low anti tumor response.


Find Patent Forward Citations

Loading…